Stabilization of Cox1p Intermediates by the Cox14p–Coa3p Complex ⇑ Gavin P
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Prioritization of Variants Detected by Next Generation Sequencing According to the Mutation Tolerance and Mutational Architecture of the Corresponding Genes
International Journal of Molecular Sciences Review Prioritization of Variants Detected by Next Generation Sequencing According to the Mutation Tolerance and Mutational Architecture of the Corresponding Genes Iria Roca, Ana Fernández-Marmiesse, Sofía Gouveia, Marta Segovia and María L. Couce * Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain; [email protected] (I.R.); [email protected] (A.F.-M.); sofi[email protected] (S.G.); [email protected] (M.S.) * Correspondence: [email protected]; Tel.: +34-981-950-102 Received: 3 April 2018; Accepted: 23 May 2018; Published: 27 May 2018 Abstract: The biggest challenge geneticists face when applying next-generation sequencing technology to the diagnosis of rare diseases is determining which rare variants, from the dozens or hundreds detected, are potentially implicated in the patient’s phenotype. Thus, variant prioritization is an essential step in the process of rare disease diagnosis. In addition to conducting the usual in-silico analyses to predict variant pathogenicity (based on nucleotide/amino-acid conservation and the differences between the physicochemical features of the amino-acid change), three important concepts should be borne in mind. The first is the “mutation tolerance” of the genes in which variants are located. This describes the susceptibility of a given gene to any functional mutation and depends on the strength of purifying selection acting against it. The second is the “mutational architecture” of each gene. This describes the type and location of mutations previously identified in the gene, and their association with different phenotypes or degrees of severity. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Boykov Our Findings Caution Against the Use of Indiscriminate
GRAPHICAL ABSTRACT RESULTS cont Our findings OXPHOS Kinetics 150 caution against 100 Colon 50 CT26.WT the use of of max JO2 % Heart 0 indiscriminate OligomycinFCCP FCCP[1µM] FCCP[2µM] FCCP[3µM] [4µM] GATPGATP (-54.16)GATP (-58.93)GATP (-60.64) (-61.49)FCCP [0.5µM] Δ Δ Δ Δ mitochondrial Figure 3 Respiration in permeabilized colon and heart strips and in permeabilized cells, depicted as a RESULTS % of max respiration. inhibitors for Mitochondrial Bioenergetics ATP/O ratio OXPHOS proteome Figure 1 Figure 2 Pooled OXPHOS Expression cancer treatment. OXPHOS Kinetics (per mg cellular protein) Respiratory Capacity (per mg cellular protein) OXPHOS 8000 8000 * Efficiency 100 * Colon * * * ns * * * 6000 CT26.WT 6000 * * ns 50 Heart * * 2.0 * * * ns 4000 * * 4000 * * * 1.5 (pmol/s/mg) 0 * Max of Percent (pmol/s/mg) 2 Ilya Boykov 2 2000 * * 2000 CI CII CIII CIV CV JO * JO * * * * * 1.0 * * Mentor: Kelsey Fisher-Wellman * (pmol/s/mg) Mitochondrial Complex * 2 0 0 0.5 Figure 4: Mitochondrial complex enrichment Department of Physiology JO depicted as % of max content for each P/M P/M CytC CytC PCRPCRPCR Basal BasalClamp Oligo complex Oct/Suc Rot/Anti Oct/Suc Rot/Anti 0.0 1uM FCCP2uM FCCP3uM FCCP4uM FCCP 1uM 2uMFCCP 3uMFCCP 4uMFCCP FCCP 0.5uM FCCP 0.5uM FCCP Complex IV proteome P/O Colon P/O Heart Figure 5 In situ quantification of mitochondrial OXPHOS Kinetics Respiratory Capacity P/O CT26.WT (per mg mitochondrial protein) (per mg mitochondrial protein) Cox7c 20000 Figure 2: Mitochondrial bioenergetics reveals disparate 20000 COX2 * * * * * P/O ratio in mitochondria Cox6b1 * * with 100uM ADP Cox6c OXPHOS kinetics between mouse 15000 * * 15000 * energized with Succinate Cox7a1 * * COX1 1 colorectal cancer cells and healthy * and Octanoyl-L-carnitine. -
Biogenesis of Cytochrome C Oxidase — in Vitro Approaches to Study Cofactor Insertion Into a Bacterial Subunit I
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1777 (2008) 904–911 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbabio Review Biogenesis of cytochrome c oxidase — in vitro approaches to study cofactor insertion into a bacterial subunit I Peter Greiner ⁎, Achim Hannappel, Carolin Werner, Bernd Ludwig Institute for Biochemistry, Molecular Genetics, Johann-Wolfgang-Goethe University, Max-von-Laue Straβe 9, 60438 Frankfurt am Main, Germany ARTICLE INFO ABSTRACT Article history: Biogenesis of cytochrome c oxidase is a complex process involving more than 30 known accessory proteins in Received 30 November 2007 yeast for the regulation of transcription and translation, membrane insertion and protein processing, cofactor Received in revised form 25 March 2008 insertion, and subunit assembly. Here, we focus on the process of cofactor insertion into subunit I of Accepted 2 April 2008 cytochrome c oxidase using the soil bacterium Paracoccus denitrificans as a model organism. The use of Available online 10 April 2008 bacterial systems facilitates biogenesis studies, as the number of required assembly factors is reduced to a Keywords: minimum. Both, co- and posttranslational cofactor insertion scenarios are discussed, and several approaches Assembly to shed light on this aspect of biogenesis are presented. CtaG, the Paracoccus homolog of yeast Cox11 which is fi Cox11 involved in copper delivery to the CuB center, has been puri ed and characterized spectroscopically. A Copper chaperone previously unreported signal at 358 nm allows monitoring copper transfer from copper-loaded CtaG to an Heme a acceptor. -
WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US). -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Mirc11 Disrupts Inflammatory but Not Cytotoxic Responses of NK Cells
Published OnlineFirst September 12, 2019; DOI: 10.1158/2326-6066.CIR-18-0934 Research Article Cancer Immunology Research Mirc11 Disrupts Inflammatory but Not Cytotoxic Responses of NK Cells Arash Nanbakhsh1, Anupallavi Srinivasamani1, Sandra Holzhauer2, Matthew J. Riese2,3,4, Yongwei Zheng5, Demin Wang4,5, Robert Burns6, Michael H. Reimer7,8, Sridhar Rao7,8, Angela Lemke9,10, Shirng-Wern Tsaih9,10, Michael J. Flister9,10, Shunhua Lao1,11, Richard Dahl12, Monica S. Thakar1,11, and Subramaniam Malarkannan1,3,4,9,11 Abstract Natural killer (NK) cells generate proinflammatory cyto- g–dependent clearance of Listeria monocytogenes or B16F10 kines that are required to contain infections and tumor melanoma in vivo by NK cells. These functional changes growth. However, the posttranscriptional mechanisms that resulted from Mirc11 silencing ubiquitin modifiers A20, regulate NK cell functions are not fully understood. Here, we Cbl-b, and Itch, allowing TRAF6-dependent activation of define the role of the microRNA cluster known as Mirc11 NF-kB and AP-1. Lack of Mirc11 caused increased translation (which includes miRNA-23a, miRNA-24a, and miRNA-27a) of A20, Cbl-b, and Itch proteins, resulting in deubiquityla- in NK cell–mediated proinflammatory responses. Absence tion of scaffolding K63 and addition of degradative K48 of Mirc11 did not alter the development or the antitumor moieties on TRAF6. Collectively, our results describe a func- cytotoxicity of NK cells. However, loss of Mirc11 reduced tion of Mirc11 that regulates generation of proinflammatory generation of proinflammatory factors in vitro and interferon- cytokines from effector lymphocytes. Introduction TRAF2 and TRAF6 promote K63-linked polyubiquitination that is required for subcellular localization of the substrates (20), Natural killer (NK) cells generate proinflammatory factors and and subsequent activation of NF-kB (21) and AP-1 (22). -
Coa3 and Cox14 Are Essential for Negative Feedback Regulation of COX1 Translation in Mitochondria
JCB: Article Coa3 and Cox14 are essential for negative feedback regulation of COX1 translation in mitochondria David U. Mick,1,2,3 Milena Vukotic,3 Heike Piechura,4 Helmut E. Meyer,4 Bettina Warscheid,4,5 Markus Deckers,3 and Peter Rehling3 1Institut für Biochemie und Molekularbiologie, Zentrum für Biochemie und Molekulare Zellforschung and 2Fakultät für Biologie, Universität Freiburg, D-79104 Freiburg, Germany 3Abteilung für Biochemie II, Universität Göttingen, D-37073 Göttingen, Germany 4Medizinisches Proteom-Center, Ruhr-Universität Bochum, D-44801 Bochum, Germany 5Clinical and Cellular Proteomics, Duisburg-Essen Universität, D-45117 Essen, Germany egulation of eukaryotic cytochrome oxidase assem- newly synthesized Cox1 and are required for Mss51 as- bly occurs at the level of Cox1 translation, its central sociation with these complexes. Mss51 exists in equilibrium Rmitochondria-encoded subunit. Translation of COX1 between a latent, translational resting, and a committed, messenger RNA is coupled to complex assembly in a neg- translation-effective, state that are represented as distinct ative feedback loop: the translational activator Mss51 is complexes. Coa3 and Cox14 promote formation of the thought to be sequestered to assembly intermediates, ren- latent state and thus down-regulate COX1 expression. dering it incompetent to promote translation. In this study, Consequently, lack of Coa3 or Cox14 function traps Mss51 we identify Coa3 (cytochrome oxidase assembly factor 3; in the committed state and promotes Cox1 synthesis. Our Yjl062w-A), a novel regulator of mitochondrial COX1 data indicate that Coa1 binding to sequestered Mss51 in translation and cytochrome oxidase assembly. We show complex with Cox14, Coa3, and Cox1 is essential for that Coa3 and Cox14 form assembly intermediates with full inactivation. -
Mitochondrial Medicine in the Omics Era
Mitochondrial Medicine in the Omics Era Joyeeta Rahman1 and Shamima Rahman1,2* 1 Mitochondrial Research Group, UCL Great Ormond Street Institute of Child Health and 2 Metabolic Unit, Great Ormond Street Hospital NHS Foundation Trust, London, UK *Correspondence to: Professor Shamima Rahman Mitochondrial Research Group Genetics and Genomic Medicine UCL Great Ormond Street Institute of Child Health London WC1N 1EH, UK. Telephone: +44 (0)2079052608 [email protected] Keywords: Mitochondrial disease, OXPHOS, signalling, omics, genomics, transcriptomics, proteomics, metabolomics, mitochondrial stress response, treatment 1 Abstract Mitochondria are dynamic bioenergetic organelles whose maintenance requires ~1500 proteins from two genomes. Mutations in either the mitochondrial or nuclear genome can disrupt a plethora of cellular metabolic and homeostatic functions. Mitochondrial diseases represent one the most common and severe groups of inherited genetic disorders, characterised by clinical, biochemical, and genetic heterogeneity, diagnostic odysseys, and lack of curative therapies. This review aims to discuss recent advances in mitochondrial biology and medicine arising from widespread utilisation of high-throughput omics technologies, and also includes a broad discussion of emerging therapies for mitochondrial disease. New insights into both bioenergetic and biosynthetic mitochondrial functionalities have expedited the genetic diagnosis of primary mitochondrial disorders, and identified novel mitochondrial pathomechanisms and new targets -
Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in -
Mitochondrial Dysfunction and Its Role in Tissue-Specific Cellular Stress
Review www.cell-stress.com Mitochondrial dysfunction and its role in tissue-specific cellular stress David Pacheu-Grau1,*, Robert Rucktäschel1 and Markus Deckers1,* 1 Department of Cellular Biochemistry, University Medical Center Göttingen, Germany. * Corresponding Authors: David Pacheu-Grau, University Medical Center Göttingen, Department of Cellular Biochemistry, Humboldtallee 23, 37073 Göttingen, Germany. Phone: +49-(0)551-394571; E-mail: [email protected]; Markus Deckers, University Medical Center Göttingen, Department of Cellular Biochemistry, Humboldtallee 23, 37073 Göttingen, Germany. Phone: +49-(0)551-395983; E-mail: [email protected] ABSTRACT Mitochondrial bioenergetics require the coordination of two dif- doi: 10.15698/cst2018.07.147 ferent and independent genomes. Mutations in either genome will affect mi- Received originally: 26.04.2018 tochondrial functionality and produce different sources of cellular stress. De- in revised form: 13.06.2018, Accepted 14.06.2018, pending on the kind of defect and stress, different tissues and organs will be Published 13.07.2018. affected, leading to diverse pathological conditions. There is no curative ther- apy for mitochondrial diseases, nevertheless, there are strategies described that fight the various stress forms caused by the malfunctioning organelles. Keywords: mitochondrial dysfunction, Here, we will revise the main kinds of stress generated by mutations in mito- cellular stress, mitochondrial chondrial genes and outline several ways of fighting this stress. pathology, therapy. Abbreviations: ADOA – autosomal dominant optic atrophy, AROA – autosomal recessive optic atrophy, ARS – aminoacyl-tRNA synthetase, CL – cardiolipin, CRISPR – clustered regularly interspaced short palindromic repeats, LHON – Leber’s hereditary optic neuropathy, mt - mitochondrial OXPHOS – oxidative phosphorylation, ROS – reactive oxygen species. -
Long Non‑Coding RNA AK055347 Is Upregulated in Patients with Atrial Fibrillation and Regulates Mitochondrial Energy Production in Myocardiocytes
MOLECULAR MEDICINE REPORTS 14: 5311-5317, 2016 Long non‑coding RNA AK055347 is upregulated in patients with atrial fibrillation and regulates mitochondrial energy production in myocardiocytes GUIYING CHEN*, HONG GUO*, YING SONG, HUIYING CHANG, SHAOJUN WANG, MIAOMIAO ZHANG and CHANG LIU Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China Received September 10, 2015; Accepted September 22, 2016 DOI: 10.3892/mmr.2016.5893 Abstract. The role of long non-coding RNAs (lncRNAs) in and mortality. However, the etiology of AF is complex and atrial fibrillation remains to be fully elucidated. The current unclear, and inherited and environmental factors have been study performed microarray analysis to investigate differen- reported to be involved (5,6). tial lncRNA expression profiling in atrial samples from the The progression of AF is commonly accompanied with pulmonary vein and the surrounding left atrial area (LA‑PV) alterations in gene expression, thus resulting in abnormal protein and from the left atrial appendage (LAA) in 16 patients expression expression (7,8). A previous study identified that long with atrial fibrillation (AF). Microarray analysis identified non‑coding RNAs (lncRNAs), endogenous RNAs >200 nucleo- 94 lncRNAs that were differentially expressed between the tides in length that do not code for functional proteins, regulate LA‑PV and LAA in patients with AF. AK055347 was one the gene expression of numerous proteins (9). Several studies of lncRNAs with the most significant alterations observed. have demonstrated that lncRNAs are associated with diseases Knockdown of AK055347 inhibited cell viability of H9C2 including cancer (10), endocrine diseases (11), liver diseases (12) cardiomyocytes, accompanied by downregulation of Cyp450 and heart diseases (13,14).